JavaScript отключён. Чтобы полноценно использовать наш сайт, включите JavaScript в своём браузере.

Ответить в теме

Сообщение: <blockquote data-quote="Morrissambit" data-source="post: 998249" data-attributes="member: 85778">Hxwj This Canadian Stock Could Be a Huge Winner in the Post-COVID WorldHydro One  TSX:H  operates a highly regul <a href="https://www.stanley-cups.uk">stanley cup</a> ated electricity transmission and distribution business, serving 1.5 million customers in Ontario. Its financials are less susceptible to market volatility, given a 99% rate-regulated utility business and no exposure to commodity price fluctuations. Supported by these solid financials, the company has delivered over 133% returns in the last five years at an annualized rate of 18.5%. Besides, the company   stock price <a href="https://www.stanley-cup.pl">stanley cup</a>  is up 18.4% this year, outperforming the broader equity markets. Let   assess buying opportunities in the stock by looking at its recent second- <a href="https://www.stanleycups.it">stanley cup</a> quarter performance and growth prospects.Hydro One s Q2 performanceHydro One reported revenue of $2 billion during the second quarter, representing a 9.4% increase from the previous year. However, its revenues, net of purchased power, grew 3% to $1.1 billion amid favourable rate revisions and higher demand. Meanwhile, its OMA  operation, maintenance, and administration  expe Soyf Why Bombardier Stock Soared 10% This WeekAfter a choppy start to 2018 for the Canadian stock market, the SP/TSX Composite Index managed to put together a rally in late April. Investors on the hunt for growth should not only target quality companies, but those that are involved in growing industries. Today, we will focus on three stocks that fit the bill and could yield explosive gains <a href="https://www.stanley-cups.at">stanley cup</a>  in the long term.Zymeworks Inc.  TSX:ZYME  NYSE:ZYME Zymeworks is a Vancouver-based clinical-stage biopharmaceutical company. Shares have surged in 2018 after the stock sputtered for much of t <a href="https://www.stanley-mugs.us">stanley mugs</a> he previous year. The flagship product offered by Zymeworks is ZW25, an antibody designed to target gastric, ovarian, and breast cancer tumours.In the first quarter, Zymeworks <a href="https://www.stanley-cups.com.de">stanley cups</a>  announced the opening of new sites in Canada and the United States for its adaptive phase-one study of ZW25. According to research from Global Market Insights Inc., the breast cancer therapeutics market is expected to grow to over $28 billion by 2024. This is in large part due to</blockquote>

Имя

Проверка